Compare IOSP & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOSP | TSHA |
|---|---|---|
| Founded | 1938 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 1998 | 2020 |
| Metric | IOSP | TSHA |
|---|---|---|
| Price | $79.88 | $4.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $124.00 | $10.56 |
| AVG Volume (30 Days) | 174.8K | ★ 2.8M |
| Earning Date | 02-17-2026 | 02-25-2026 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,789,200,000.00 | $6,310,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $70.10 | $1.05 |
| 52 Week High | $117.08 | $6.02 |
| Indicator | IOSP | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 57.10 | 37.95 |
| Support Level | $79.41 | $4.56 |
| Resistance Level | $82.36 | $5.17 |
| Average True Range (ATR) | 1.89 | 0.34 |
| MACD | 0.14 | -0.11 |
| Stochastic Oscillator | 65.23 | 0.39 |
Innospec Inc manufactures and sells a variety of chemicals and fuel additives. The firm organizes itself into three segments based on product type. The Fuel Specialties segment, which generates the majority of revenue, sells products used to improve fuel efficiency, boost engine performance, and reduce emissions for automobiles, boats, and airplanes. It also sells products used by oil field service providers in the extraction of oil and gas. The Performance Chemicals segment sells products to the personal-care industry. The Oilfield Services segment develops and markets products to prevent loss of mud.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.